Original Article

You have full text access to this OnlineOpen article

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer

  1. Chih-Hsin Yang MD, PhD1,
  2. Jin-Yuan Shih MD, PhD2,
  3. Kun-Chieh Chen MD3,
  4. Chong-Jen Yu MD, PhD2,
  5. Tsung-Ying Yang MD3,
  6. Ching-Pei Lin RN3,
  7. Wen-Pin Su MD1,
  8. Chien-Hung Gow MD2,
  9. Chiun Hsu MD, PhD1,
  10. Gee-Chen Chang MD, PhD3,4,5,†,*,
  11. Pan-Chyr Yang MD, PhD2

Article first published online: 20 SEP 2006

DOI: 10.1002/cncr.22220

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1873–1882, 15 October 2006

Additional Information

How to Cite

Yang, C.-H., Shih, J.-Y., Chen, K.-C., Yu, C.-J., Yang, T.-Y., Lin, C.-P., Su, W.-P., Gow, C.-H., Hsu, C., Chang, G.-C. and Yang, P.-C. (2006), Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer, 107: 1873–1882. doi: 10.1002/cncr.22220

Author Information

  1. 1

    Department of Oncology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China

  2. 2

    Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China

  3. 3

    Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China

  4. 4

    School of Medicine, China Medical University, Taichung, Taiwan, Republic of China

  5. 5

    Institute of Biomedical Sciences, National Chung-Hsing University, Taichung, Taiwan, Republic of China

  1. †

    Fax: 011 (886) 423552590

*Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, 160, Chung-Kang Road, Section 3, Taichung, Taiwan, Republic of China

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 20 SEP 2006
  3. Manuscript Accepted: 21 JUL 2006
  4. Manuscript Revised: 20 JUL 2006
  5. Manuscript Received: 22 MAY 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (212K)

REFERENCES

  • 1
    Blackledge G, Averbuch S. Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004; 90: 566–572.
  • 2
    Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003; 30(1 Suppl 1 ): 30–38.
  • 3
    Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527–1537.
  • 4
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol. 2003; 21: 2237–2246.
  • 5
    Su WP, Yang CH, Yu CJ, et al. Gefitinib treatment for non-small cell lung cancer—a study including patients with poor performance status. J Formosan Med Assoc. 2005; 104: 557–562.
  • 6
    Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res. 2004; 10: 4383–4388.
  • 7
    Lim ST, Wong EH, Chuah KL, et al. Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. Br J Cancer. 2005; 93: 23–28.
  • 8
    Chang GC, Chen KC, Yang TY, et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest N Drugs. 2005; 23: 73–77.
  • 9
    Mu XL, Li LY, Zhang XT, et al. Evaluation of safety and efficacy of gefitinib (‘Iressa’, zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer. 2004; 4: 51.
  • 10
    Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res. 2005; 11: 2244–2251.
  • 11
    Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib anti-tumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol. 2006; 1: 520–525.
  • 12
    Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a Phase II study. J Clin Oncol. 2006; 24: 64–69.
  • 13
    Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res. 2005; 11: 3032–3037.
  • 14
    Kimura H, Kasahara K, Shibata K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol. 2006; 1: 260–267.
  • 15
    Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207–214.
    Direct Link:
  • 16
    Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2006; 118: 963–969.
    Direct Link:
  • 17
    Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med. 2005; 353: 207–208.
  • 18
    Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004; 43: 317–322.
  • 19
    Spigel DR, Hainsworth JD, Burkett ER, et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II trial. Clin Lung Cancer. 2005; 7: 127–132.
  • 20
    Yang CH, Yu CJ, Chen KY, et al. A Phase II study of gefitinib as first-line treatment for good performance advanced or metastatic nonsmall cell lung cancer in East Asian patients. 2006 ASCO annual meeting proceedings. J Clin Oncol. 2006; 24(18S): 7176. Abstract.
  • 21
    Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330–353.
  • 22
    Kuo SH, Yang CH, Yu CJ, et al. Survival of Stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials. Lung Cancer. 2005; 48: 275–280.
  • 23
    Ferguson MK, Skosey C, Hoffman PC, et al. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990; 8: 1402–1407.
  • 24
    Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995; 13: 1221–1230.
  • 25
    Hotta K, Inoue A, Kiura K, et al. Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. Lung Cancer. 2005; 50: 413–415.
  • 26
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–2139.
  • 27
    Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005; 11: 1167–1173.
  • 28
    Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005; 23: 2493–2501.
  • 29
    Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004; 10: 8195–8203.
  • 30
    Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6829–6837.
  • 31
    Zhang XT, Li LY, Mu XL, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol. 2005; 16: 1334–1342.
  • 32
    Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005; 23: 2513–2520.
  • 33
    Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005; 11: 4289–4294.
  • 34
    Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005; 11: 3750–3757.
  • 35
    Nagai Y, Miyazawa H, Hugon B, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005; 65: 7276–7282.
View Full Article (HTML) Get PDF (212K)